For more than 100 years, veterinarians have been forced to rely on slow and unreliable traditional culturing diagnostics of the past, whereas human diagnostic technology has taken a giant step forward. MicroGen Vet is here to change that. We will bring DNA-based Next Generation Sequencing (NGS) diagnostics to the veterinary marketplace as the exclusive reseller of MicroGen DX diagnostic services. 

MicroGen DX is the market leader in providing this cutting edge technology to the human diagnostics market - with over 9 years in operation and 300K tests run on human patients. (Source) Now, it's time for veterinarians to benefit from this technology. We bring accurate, quick, and affordable NGS testing services directly from MicroGen DX's laboratories, meaning we're able to immediately fold into the already high volume of human tests, keeping costs low. 

We're the exclusive reseller of this technology that is changing the way vets diagnose their patients. As the understanding of biofilms grows, the need for accurate identification of all microbes in an infection is becoming more and more critical. Veterinary Research Universities have already begun to research the many advantages of this technology. 

In fact, MicroGen Vet is already supporting clinical trials on over 200 horses with both the Rood & Riddle Equine Hospital and Colorado State University's Equine Reproductive Laboratory. Our plan is to make inroads in the U.S. equine and small-animal markets, and then expand to exotic/zoo and livestock markets, and then to grow into international veterinary markets for each.

*National Institutes of Health

*J.W. Costerton, 

Center For Genomic Sciences

*Dr. Michael Walters, DO

Urologist, Foley AL

*Centers for Disease Control

• There are fewer regulation and billing requirements in the vet market than the human market - this means rapid growth for us.
• The barrier to entry is high and price competitiveness only comes with high testing volume, which we have with MicroGen DX. 
• Market education is straightforward through clinical trials and grand round sessions with leading Veterinary Research Universities.
• Simplified test acquisition is made possible through existing veterinary distribution and channel partners, which also simplifies the operational model for MicroGen Vet.
• Our Investment dollars will primarily fuel market education efforts and the creation of regional sales and channel teams to drive growth through our business partners.
• Focused efforts in the U.S. equine and small animal veterinary health markets with expansion to exotic/zoo and livestock markets followed with geographical expansion beyond U.S. markets will lead to sustained growth for the business

• UNIQUE: Next Generation Sequencing (NGS) is the next step beyond Traditional Culture Testing.
• NECESSARY: We estimate that over 40 million cultures are performed each year in our targeted markets.
• EXCLUSIVITY: MicroGen DX provides NGS diagnostic services exclusively for MicroGen Vet customers in global veterinary markets.

• MicroGenDX provides NGS diagnostics as a service. Sample kits are purchased through distribution or online resellers, and samples are simply overnighted to labs for testing.

• A Level 1 PCR panel report is provided to customer within 24 hrs. It identifies bacteria load, presence of common microbes & antibiotic resistance genes.

• The Level 2 NGS report is provided to customer within 3-4 days. It identifies every microbe present, along with a list of common antibiotics used for identified microbes.

• We're able to keep costs low by merging with the high volume of MicroGen DX tests through the same laboratories (DNA is DNA)

• FRAGILE: Samples must follow strict guidelines of being at the lab within 2 hours - and they must be kept at room temperature
• UNRELIABLE: Cultures have a high incidence of returning results as "no growth" because less than 1% of known microbes will grow in traditional cultures
• LENGTHY PROCESS: Can take 20 days for results 

• STABLE: Samples are not effected by time and temperature
• ACCURATE: We extract microbial DNA directly from the source (rather than growing it - like traditional cultures). This is similar to finger printing at a crime scene 
• QUICK RESULTS: Results within 3-5 days with 99.9% accuracy 
• ANTIBIOTIC RESISTANCE DETECTION: Additionally, we're able to to detect antibiotic resistance genes for 8 antibiotic classes and deliver associated antibiotics information sheet for each patient. 

Chronic infections and biofilm education will initially be the focus of the business.  We believe that the Total Attainable Market for sales of NGS services is estimated at:

• 5-10 Million tests/year 
• $1 Billion to $2.1 Billion per year

Currently, we are focused initially on equine and small-animal markets but have already received significant interest from national zoos and livestock practitioners. Additionally, we have been contacted by potential partners in Latin America and Canada, which represent significant expansion opportunities in 2019 and beyond.

• We initially launched at the AAEP Conference in San Antonio in November 2017 and VMX Conference in Orlando in February 2018.
• Already, MicroGen Vet test kits are distributed through MWI Animal Health and Miller Vet Supply and through online reseller VetCove, with additional channels under review. 
• Clinical Trials are underway at Rood & Riddle Equine Hospital and at the Colorado State University Equine Reproductive Lab, with several others to come.